{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280186","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.305471+00:00","generated_at":"2026-06-22T04:23:25.593128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biote Q3 revenue $42M (+18% YoY); expects upper end of 2022 guidance","bullets":["Revenue $42.0M, up 18% YoY; net loss $(6.3)M, GAAP diluted EPS $(1.74) due to transaction costs.","Adjusted EBITDA $12.2M (+19% YoY); expects upper end of 2022 revenue $160-$166M and adj. EBITDA $47-$51M.","Gross margin improved to 68.2% from 65.4% on favorable product mix.","Operating income $7.8M, down 13% due to $3.1M transaction and legal costs.","Cash from operations $6.4M in Q3; sales force expansion on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280186","json":"https://secwatch.observer/filing/0001193125-22-280186.json","markdown":"https://secwatch.observer/filing/0001193125-22-280186.md","text":"https://secwatch.observer/filing/0001193125-22-280186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312522280186/0001193125-22-280186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312522280186/d402691d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:23:25.593128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a85ad3bdae5088f8980200d3b2bc3c68dce3ad39","claim":"biote Corp. reported the third quarter ended September 30, 2022 results: revenue $42.0 million, net income $(6.3) million, EPS $(1.74). Guidance reaffirmed.","evidence_excerpt":"set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX – November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312522280186/0001193125-22-280186-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$42.0 million"},{"label":"Net income","value":"$(6.3) million"},{"label":"EPS","value":"$(1.74)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}